Seven US Democratic Senators are reportedly calling or regulators to review the proposed acquisition of Allergan, which makes Botox, by Canada’s Valeant Pharmaceuticals.
According to reports, lawmakers want the $54 billion hostile takeover offer reviewed, citing former Valeant buyouts that lead to job cuts.
The company reportedly cut hundreds of jobs in …read more
Source: Global Competition Law Blogs